biotech investing argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
biotech investing argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
biotech investing argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
biotech investing argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
biotech investing argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease
biotech investing argenx Announces VYVGART SC Prefilled Syringe for Self-Injection in Chronic Inflammatory Demyelinating Polyneuropathy Authorized for Sale by Health Canada
biotech investing argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
biotech investing argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
CHARBONE devoile son plan strategique 2026-2030 : une transformation vers un groupe integre de gaz industriels a haute valeur
CHARBONE Unveils its 2026-2030 Strategic Plan: A Transformation Towards an Integrated High-Value Industrial Gas Group
RETRANSMISSION: Metalsource Mining Intersects 48.04 g/t AuEq over 12.62m, Including 210.72 g/t AuEq over 2.74m, Extends Mineralization down Dip 195m, Continues to Expand Gold, Silver and Base Metal Mineralization
Syntholene Energy Signs Site Lease and Receives Construction Permit at Historic Husavik Power Station for Demonstration Facility
